Aurealis Therapeutics offers a 4‑in‑1 multi‑target cell and gene therapy platform that creates engineered cellular products to modulate the tissue microenvironment and address multiple disease pathways in one treatment. The platform is used to develop therapies for chronic non‑healing wounds such as diabetic foot and venous leg ulcers, as well as aggressive solid tumors, with pre‑clinical and Phase 2 clinical data supporting safety, efficacy, and cost‑effectiveness.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic non‑healing wounds such as diabetic foot ulcers and venous leg ulcers, as well as individuals with aggressive, multi‑factorial cancers, have limited therapeutic options that address the underlying tissue microenvironment and disease complexity.
Solution
Aurealis Therapeutics has developed a 4‑in‑1 multi‑target cell and gene therapy platform that delivers engineered cellular products designed to modulate the tissue microenvironment and simultaneously address multiple disease pathways. The platform enables the creation of therapies such as AUP‑16 for chronic wounds and AUP‑55 for oncology, which combine gene‑edited cells, cytokine expression, and tissue‑repair mechanisms in a single treatment. Pre‑clinical studies and Phase 2 clinical data (e.g., the DIAMEND trial for diabetic foot ulcers) demonstrate safety, efficacy, and health‑economic benefits. The approach is intended to accelerate translation from laboratory to clinic, providing clinicians with a biologically active therapy that can promote wound closure or inhibit tumor progression where conventional treatments fall short.
Target Audience
Primary customers are wound‑care clinicians, dermatologists, and vascular surgeons treating chronic ulcers, as well as oncologists and cancer centers managing ovarian, peritoneal, bladder, and melanoma cancers. The platform also appeals to pharmaceutical partners seeking advanced cell‑gene therapy technologies.
Features
- Integrated cell‑gene engineering platform that delivers multiple therapeutic payloads (e.g., growth factors, anti‑inflammatory cytokines, tumor‑targeting agents) in a single product
- Ability to modulate the local tissue microenvironment to enhance regeneration in chronic wounds or alter immune infiltration in solid tumors
- Scalable manufacturing process compliant with GMP standards for autologous and allogeneic cell therapies
- Robust pre‑clinical validation pipeline including in‑vivo models of diabetic foot ulcers, venous leg ulcers, and various solid tumors
- Clinical development program with completed Phase 2 trials (DIAMEND) and ongoing preparation for pivotal Phase 3 studies
- Health‑economic modeling to demonstrate cost‑effectiveness and potential reductions in long‑term care expenditures